Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05671055 · ClinicalTrials.gov registry record
CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis
A clinical trial of Multiple Sclerosis, sponsored by icometrix.
- Completed
- Registry status
- 300
- Enrollment target
- 10
- Study locations
NCT05671055: Completed study of Multiple Sclerosis, sponsored by icometrix.
NCT05671055 is a study of Multiple Sclerosis that has completed, run by icometrix. The registered enrollment target is 300 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05671055, a study of Multiple Sclerosis, has completed, sponsored by icometrix.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 10
- Study locations
Study Summary
The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as measured on magnetic resonance imaging (MRI). Additionally, the study will provide insights into patients' experiences with cognition, and the usability of the used objective cognitive assessments.
Primary Outcome
The Neuro-QoL (Quality of Life in Neurological Disorders) is a patient-reported outcome for subjective cognitive problems Minimum and maximum values: 8-40 (t-score: 17.3-64.2). High scores indicate better (desirable) self-reported health.
Conditions Studied
Interventions
- OTHER Custom study version of icompanion app
Study Locations (10)
Other
- GZA Antwerpen - Antwerp
- Imelda Ziekenhuis - Bonheiden
- AZ Sint-Jan Brugge - Bruges
- UZ Brussel - Jette
- University of Greifswald - Greifswald
Colorado
- UCHealth - Aurora
- Brain Health Center of the Rockies - Fort Collins
New York
- Dent Neurologic Institute - Buffalo
Ohio
- The Boster Center for Multiple Sclerosis - Columbus
Texas
- Texas Neurology - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-01-07 |
| Est. Completion | 2023-12-06 |
What the finished NCT05671055 record still lists
NCT05671055 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Custom study version of icompanion app is the first listed.
NCT05671055 lists 10 locations in 5 states (Other, Colorado, New York).
Frequently Asked Questions
What is clinical trial NCT05671055 about?
NCT05671055 is a clinical study titled "CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis". The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as mea...
What is the current status of trial NCT05671055?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2023-01-07. Estimated completion is 2023-12-06.
What conditions does trial NCT05671055 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05671055?
The interventions under investigation include: Custom study version of icompanion app (OTHER).
Who is sponsoring clinical trial NCT05671055?
This trial is sponsored by icometrix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05671055 being conducted?
This trial has 10 study locations across Colorado, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05671055's enrollment target sits among peer trials
300 56th of 315 higher than 256 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI